RE:RE:Partnership coming $ 640 million to $740 million.
-French Canada company like Valeant
-small target population to the point that FDA refused to give TST orphan drug designation
-regulatory risk, yeah right lets continue to use BCG but just between shortage
-emerging competition like may be 2020 if they pass P3 and FDA. funny how the companies that are only in P1/2 are more valued and less risky than a P3 company that FDA is aware of.
So before you said that the analyst could not jump to $3 right away but now $1.5 is fine.
"nobody willing to pay 45 cents"? some did at .5x just last week.
anyway i have no warants so i don't count the day.
Roche trial is called IMVIGOR, TST have a brand name for IMVYON. you wonder.